Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Research & Development (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Research & Development for 7 consecutive years, with $166.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 74.22% year-over-year to $166.6 million, compared with a TTM value of $559.2 million through Dec 2025, up 84.18%, and an annual FY2025 reading of $559.2 million, up 84.18% over the prior year.
  • Research & Development was $166.6 million for Q4 2025 at Avidity Biosciences, up from $154.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $166.6 million in Q4 2025 and bottomed at $20.7 million in Q1 2021.
  • Average Research & Development over 5 years is $65.3 million, with a median of $47.7 million recorded in 2023.
  • The sharpest move saw Research & Development soared 272.96% in 2021, then grew 7.25% in 2023.
  • Year by year, Research & Development stood at $33.0 million in 2021, then soared by 38.35% to $45.6 million in 2022, then grew by 15.8% to $52.8 million in 2023, then surged by 81.05% to $95.6 million in 2024, then skyrocketed by 74.22% to $166.6 million in 2025.
  • Business Quant data shows Research & Development for RNA at $166.6 million in Q4 2025, $154.9 million in Q3 2025, and $138.1 million in Q2 2025.